Milameline Explained

Milameline (CI-979, PD-129,409, RU-35,926) is a non-selective muscarinic acetylcholine receptor partial agonist with cognition-acting properties that was being investigated for the treatment of Alzheimer's disease, but produced poor results in clinical trials and was subsequently discontinued.^[1]

• Changing the O-methyl aldoxime to an O-propargyl oxime instead gives a separate molecule called RU 35986.^[2]

See also

• Alvameline
• Sabcomeline
• Tazomeline
• Xanomeline

Notes and References

1. Sedman AJ, Bockbrader H, Schwarz RD . Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease . Life Sciences . 56 . 11–12 . 877–882 . 1995 . 10188788 . 10.1016/0024-3205(95)00023-Y.
2. Broadley KJ, Kelly DR . Muscarinic Receptor Agonists and Antagonists . Molecules . 6 . 3 . 2001 . 142–193 . 1420-3049 . 10.3390/60300142 . 6236374 . free .